4,059,054 Shares in Century Therapeutics, Inc. $IPSC Bought by Spruce Street Capital LP

Spruce Street Capital LP purchased a new position in shares of Century Therapeutics, Inc. (NASDAQ:IPSC) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 4,059,054 shares of the company’s stock, valued at approximately $9,944,682. Century Therapeutics makes up about 0.0% of Spruce Street Capital LP’s holdings, making the stock its 16th largest position. Spruce Street Capital LP owned about 2.25% of Century Therapeutics as of its most recent filing with the SEC.

Other hedge funds also recently made changes to their positions in the company. Seven Fleet Capital Management LP bought a new position in Century Therapeutics during the 1st quarter valued at approximately $9,826,000. Commodore Capital LP purchased a new position in Century Therapeutics during the first quarter worth approximately $19,652,000. Rock Springs Capital Management LP purchased a new stake in Century Therapeutics during the 1st quarter worth about $2,948,000. Versant Venture Management LLC purchased a new stake in Century Therapeutics during the 1st quarter valued at approximately $27,495,000. Finally, DV Trading LLC acquired a new stake in shares of Century Therapeutics in the first quarter valued at approximately $3,164,000. 50.20% of the stock is currently owned by hedge funds and other institutional investors.

Century Therapeutics Trading Down 9.0%

Shares of IPSC traded down $0.20 during mid-day trading on Friday, hitting $2.03. 482,568 shares of the company’s stock were exchanged, compared to its average volume of 1,369,252. Century Therapeutics, Inc. has a fifty-two week low of $0.44 and a fifty-two week high of $3.04. The business’s 50 day moving average is $2.17 and its two-hundred day moving average is $2.22. The firm has a market capitalization of $367.58 million, a P/E ratio of -2.18 and a beta of 1.57.

Century Therapeutics (NASDAQ:IPSC) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.06). On average, equities research analysts forecast that Century Therapeutics, Inc. will post -0.47 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms recently weighed in on IPSC. Wall Street Zen downgraded shares of Century Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, June 27th. Weiss Ratings reissued a “sell (d-)” rating on shares of Century Therapeutics in a research note on Thursday, July 2nd. Finally, Mizuho began coverage on Century Therapeutics in a research note on Wednesday, May 27th. They issued an “outperform” rating and a $8.00 target price on the stock. Four analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $4.75.

About Century Therapeutics

Century Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of allogeneic cell therapies for cancer. Utilizing induced pluripotent stem cell (iPSC) technology, the company engineers “off-the-shelf” natural killer (NK) and T cell candidates designed to target hematologic malignancies and solid tumors. By harnessing iPSC-derived immune cells, Century aims to overcome challenges associated with patient-derived therapies, such as manufacturing variability and treatment delays.

The company’s proprietary platform integrates gene editing, synthetic biology and scalable cell expansion processes to generate a pipeline of product candidates.